EDC1 is an antibody drug conjugate that has been shown to cure primary pancreatic cancers in laboratory animals when in combination with gemcitabine, a standard of care medicine. EDC1 targets and binds to a complex found on multiple forms of metastatic cancer, including untreatable pancreatic cancers. EDC1 also destroys the surrounding stroma which protects and feeds the cancer. When EDC1 finds its two targets, it binds and kills cancer cells by an novel mechanism which leads to an increase in immune recognition markers, followed by cell death. 

EDC1 Report

EDC1 - Antibody Target

EDC1 – Warhead Target